– CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminary data from at least 5mg/kg dose cohort expected second half 2024 – Phase 2 CONNECT1-EDO51 Clinical Trial of PGN-EDO51: In March 2024, PepGen announced that the 5 mg/kg PGN-EDO51 dose cohort was fully enrolled. PepGen expects to report preliminary data from this cohort in mid-2024, including initial safety, exon 51 skipping, and dystrophin production data. CONNECT1-EDO51 is a Phase 2, open-labe ...

PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights potentially support a future accelerated approval pathway, subject to regulatory authority feedback. – CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminary data from at least 5mg/kg dose cohort expected second half 2024 – – Net proceeds of $86.3 million from common stock offerings extending cash runway into 2026 – BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- PepGen In ...

PepGen, Inc. (NASDAQ:PEPG) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Emiko Bryant - Chief of Staff James McArthur - President and CEO Michelle Mellion - SVP and Head, Clinical Development Noel Donnelly - CFO Conference Call Participants Jenny Gonzalez-Armenta - Leerink Partners James Condulis - Stifel Tazeen Ahmad - Bank of America Laura Chico - Wedbush Ananda Ghosh - H.C. Wainwright & Company Operator Good afternoon, and welcome to PepGen's Fourth Quarter and Full Year ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR (State or other jurisdiction of incorporation or organization) 321 Harrison Avenue Boston, MA 02118 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR T ...

PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments - FREEDOM-DM1 Phase 1 clinical trial enrolling DM1 patients with preliminary data for at least the 5 mg/kg dose cohort expected in the second half of 2024 - - Gross proceeds of approximately $80 million from February 2024 follow-on offering extends projected operating cash runway into 2026 - BOSTON, Mar. 6, 2024 -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-41374 PEPGEN INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-41374 PEPGEN INC. (Exact Name of Registrant as Specified in its Charter) Delaware 85-38198 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number: 001-41374 PEPGEN INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) 245 Main Street Cambridge, Massachusetts 02142 (Address of principal executive offices) (Zip Code) ( ...

PepGen Inc (NASDAQ:PEPG) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Noel Donnelly - Chief Financial Officer James McArthur - President and Chief Executive Officer Jaya Goyal - Executive Vice President, Research and Preclinical Development Michelle Mellion - Senior Vice President and Head, Clinical Development Conference Call Participants Laura Chico - Wedbush Operator Good afternoon and welcome to the PepGen Conference Call to discuss PepGen’s Fourth Quarter and Full Yea ...

NT T NT T NT T 0 100 200 300 400 Pcolce/Rplp0 (normalized to control) Untreated DM1 control 2 wks 12 wks 24 wks Protocol: PGN-EDODM1 was administered once intravenously (IV) to HSALR mice at 30 mg/kg; quadriceps muscle harvested 2, 12 or 24 weeks postadministration; graph plotted as mean ± SD; n=7 for 0 timepoint, 8 for 2- and 12-week timepoints; 5 for 24-week timepoint. Transcript levels measured by qPCR and normalized to Rplp0. NT = not treated. NHP: IND-ENABLING STUDIES DOSED THROUGH 90 MG/KG, RESULTS SU ...